Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Short-term Investments (2021 - 2025)

Historic Short-term Investments for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $42675.0.

  • InMed Pharmaceuticals' Short-term Investments rose 462.89% to $42675.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $42675.0, marking a year-over-year increase of 462.89%. This contributed to the annual value of $43384.0 for FY2025, which is 74.31% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Short-term Investments of $42675.0 as of Q4 2025, which was up 462.89% from $42859.0 recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Short-term Investments ranged from a high of $46098.0 in Q1 2022 and a low of $40582.0 during Q1 2025
  • Moreover, its 5-year median value for Short-term Investments was $43074.5 (2024), whereas its average is $43402.7.
  • Its Short-term Investments has fluctuated over the past 5 years, first plummeted by 826.55% in 2024, then skyrocketed by 462.89% in 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Short-term Investments (Quarter) stood at $45424.0 in 2021, then dropped by 5.22% to $43053.0 in 2022, then grew by 3.27% to $44462.0 in 2023, then dropped by 8.27% to $40787.0 in 2024, then increased by 4.63% to $42675.0 in 2025.
  • Its Short-term Investments was $42675.0 in Q4 2025, compared to $42859.0 in Q3 2025 and $43384.0 in Q2 2025.